Influenza remains a serious public health threat throughout the world. Vaccines and antivirals are available that can provide protection from infection. However, new viral strains emerge continuously because of the plasticity of the influenza genome, which necessitates annual reformulation of vaccine antigens, and resistance to antivirals can appear rapidly and become entrenched in circulating virus populations. In addition, the spread of new pandemic strains is difficult to contain because of the time required to engineer and manufacture effective vaccines. Monoclonal antibodies that target highly conserved viral epitopes might offer an alternative protection paradigm. Herein we describe the isolation of a panel of monoclonal antibodies derived from the IgG + memory B cells of healthy, human subjects that recognize a previously unknown conformational epitope within the ectodomain of the influenza matrix 2 protein, M2e. This antibody binding region is highly conserved in influenza A viruses, being present in nearly all strains detected to date, including highly pathogenic viruses that infect primarily birds and swine, and the current 2009 swine-origin H1N1 pandemic strain (S-OIV). Furthermore, these human anti-M2e monoclonal antibodies protect mice from lethal challenges with either H5N1 or H1N1 influenza viruses. These results suggest that viral M2e can elicit broadly cross-reactive and protective antibodies in humans. Accordingly, recombinant forms of these human antibodies may provide useful therapeutic agents to protect against infection from a broad spectrum of influenza A strains.
influenza matrix 2 protein | monoclonal | pandemic S easonal influenza epidemics hospitalize more than 200,000 people each year in the United States and kill an estimated 500,000 people worldwide (1) . The immune system affords only partial protection from seasonal strains in most individuals because of constantly arising point mutations in the viral genome, which lead to structural variability known as antigenic drift. Pandemic strains encounter even less immune resistance because of genomic reassortment events among different viruses, which result in more radical shifts in viral antigenic determinants. Consequently, pandemic influenza has the potential to cause widespread illness, death, and economic disruption. Vaccines and antiviral agents are available to counter the threat of influenza epidemics and pandemics. However, the strain composition of influenza vaccines must be determined before the influenza season on an annual basis, and predicting in advance which strains will become dominant is challenging. Moreover, the emergence of strains that evade vaccine-induced, protective immune responses is relatively rapid, which often results in inadequate protection (2) . Antiviral drugs include oseltamivir and zanamivir, which inhibit the function of the viral protein neuraminidase (NA), and adamantanes, which inhibit the ion channel function of the viral M2 protein (3, 4) . Antiviral agents are effective for sensitive virus strains but viral resistance can develop quickly and has the potential to render these drugs ineffective. In the 2008 to 2009 United States influenza season, nearly 100% of seasonal H1N1 or H3N2 influenza isolates tested were resistant to oseltamivir or adamantane antivirals, respectively (CDC Influenza Survey: http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/ weekly23.htm).
Passive immunotherapy using anti-influenza antibodies represents an alternative paradigm for preventing or treating viral infection. Evidence for the utility of this approach dates back nearly 100 y, when passive serum transfer was used during the 1918 influenza pandemic with some success (5) . Although protection provided by anti-influenza mAbs is typically narrow in breadth because of the antigenic heterogeneity of influenza viruses, several groups have recently reported protective mAbs that bind to conserved epitopes within the stem region of viral hemagglutinin (HA) (6) (7) (8) (9) . However, these epitopes appear to be restricted to a subset of influenza viruses; these anti-HA mAbs would not be expected to provide protection against viruses of the H3 and H7 subtypes. Of these, the former comprises an important component of circulating human strains (10) and the latter includes highly pathogenic avian strains that have caused mortality in humans (11, 12) .
Of the three antibody targets present on the surface of the influenza virus, the ectodomain of the viral M2 protein (M2e) is much more highly conserved than either HA or NA, which makes it an attractive target for broadly protective mAbs. Monoclonal antibodies to M2e have been shown to be protective in vivo (13) (14) (15) (16) (17) , and several groups have demonstrated protection against infection with vaccine strategies based on M2e (18) (19) (20) (21) (22) (23) . In these cases, purified M2 protein or peptides derived from M2e sequence have been used as immunogens to generate antiM2e antibodies in animals or as vaccine candidates. In the present study, we have isolated mAbs directly from human B cells that bind to the M2 protein displayed on virus particles and on virus-infected cells. Furthermore, we demonstrate that these antibodies protect mice from a lethal influenza A virus challenge and that they can recognize M2 variants derived from a wide range of human and animal influenza A virus isolates. This combination of properties may enhance the utility of these antibodies to prevent and treat influenza A virus infections. (Table S2 ). The human mAbs did not bind appreciably to a 23-amino acid synthetic peptide corresponding to the M2e domain of an H1N1 virus (A/Fort Worth/1/50) (Fig. 1B) . A chimeric derivative of the murine antiM2e mAb 14C2 (ch14C2), which was originally generated by immunization with purified M2 (24), exhibited the opposite behavior to that observed with the human mAbs, with little binding to virus but robust binding to the isolated 23mer M2e peptide with halfmaximal binding to peptide at 10 ng/mL ( Fig. 1 A and B) . Interestingly, both the human mAbs and ch14C2 bound to the surface of Madin-Darby canine kidney (MDCK) cells infected with H1N1 virus (A/Puerto Rico/8/34) with similar avidities (Fig. 1C) . It thus appears that viral epitopes recognized by the human anti-M2e mAbs are present and accessible on the surface of both virus and infected cells, although the epitope bound by ch14C2 is accessible only on the surface of infected cells. Our observation that the human anti-M2e mAbs do not bind appreciably to immobilized synthetic peptides derived from M2e, and furthermore that such peptides do not compete for binding of these antibodies to M2e expressed on the surface of mammalian cells (Fig. 1D) , supports the idea that secondary structure within the M2e epitope is important for binding by the human antibodies. That ch14C2 binds peptide immobilized on plastic suggests a lesser importance of higher order structure for binding of this mAb.
Results and Discussion
Protection from Lethal Challenges with H5N1 and H1N1 Viruses. We next examined the protective efficacy of the human anti-M2e mAbs TCN-031 and TCN-032 in a lethal challenge model of influenza infection in mice. Animals were challenged intranasally with 5 × LD 50 units of a high-pathogenicity H5N1 virus (A/ Vietnam/1203/04) and both human mAbs were protective when treatment was initiated 1 d after viral challenge. In contrast, mice that were subjected to similar treatment regimens with a subclassmatched, irrelevant control mAb 2N9, which targets the AD2 epitope of the gp116 portion of the human cytomegalovirus gB (25), or with a vehicle control were protected to a lesser extent, or not at all, resulting in 70 to 80% survival for mice treated with human mAbs versus 20% survival for control mAb and 0% survival for vehicle ( Fig. 2A) . The anti-M2e mAb ch14C2 did not confer substantial protection in this model (20% survival) ( Fig. 2A) , although this mAb has been shown to reduce the titer of virus in the lungs of mice infected with other strains of influenza virus (16) . All of the animals, including those in the TCN-031 and TCN-032 treatment groups, exhibited weight loss from days 4 to 8 postinfection, followed by a gradual increase in weight in the surviving animals through the end of the study on day 14 ( Fig. 2B ), indicating that the human anti-M2e mAbs afforded protection by reducing the severity or extent of infection rather than by completely preventing infection. Indeed, results of immunohistological and viral load analyses of lung, brain, and liver tissue from additional animals in each treatment cohort are consistent with a reduction in the spread of virus beyond the lung to the brain and also possibly liver in animals that were treated with the human antiM2e mAbs, but not with ch14C2 or the subclass-matched control mAb 2N9. The effect of the human anti-M2e mAbs on viral load in the lung versus the control mAbs was, however, more moderate (Table S3 and Fig. S4 , respectively).
To test whether protection conferred by the human anti-M2e mAbs mirrors their broad binding behavior, we performed a similar in vivo challenge study with a mouse-adapted isolate of the relatively divergent H1N1 virus A/Puerto Rico/8/34. Onehundred percent of PBS-treated or subclass-matched, control antibody-treated mice were killed by this virus, although a majority of the animals treated with the human anti-M2e mAbs TCN-031 and TCN-032 survived (60%) (Fig. 2C ). With this virus, mice treated with ch14C2 provided a similar survival benefit to that of the human anti-M2e mAbs (Fig. 2C ). Weight changes in each treatment group throughout the course of infection and its subsequent resolution followed a pattern that was similar to that of mice infected with the H5N1 virus (Fig. 2D) .
The human anti-M2e mAbs and ch14C2 bound to cell surfaceexpressed M2e from A/Vietnam/1203/04 and A/Puerto Rico/8/34 viruses ( Fig. 3B and Table S4 ) and cells infected with A/Puerto Rico/8/34 (Fig. 1C) . Mechanisms for antibody-mediated protection could include killing of infected host cells by antibodydependent cell-mediated cytotoxicity or complement-dependent cytotoxicity (13, 26) . We found in vitro evidence for both of these mechanisms with the human anti-M2e mAbs and ch14C2 ( Fig.  S5 and Fig. S6 ). An explanation for the enhanced in vivo pro- tection observed with the human anti-M2e mAbs as compared with ch14C2 following challenge by the high-pathogenicity avian virus A/Vietnam/1203/04 as compared with A/Puerto Rico/8/34 could be a result of the unique capability of the human mAbs to bind virus directly, whereas ch14C2 does not appear to bind influenza virions (Fig. 1A) . Protective properties of antibodies that bind to virus might be expected to include mechanisms such as antibody-dependent virolysis (27) and clearance via opsonophagocytosis by host cells (28). Some of these mechanisms require efficient interaction between antibodies and host Fc receptors. In our mouse-challenge experiments, all of the mAbs tested had human constant regions; however, other studies have shown that human antibodies can interact productively with murine Fc receptors (29).
Binding to the Highly Conserved N-Terminal Segment of M2e. To better understand the unique viral binding property of the human anti-M2e mAbs, we mapped their binding sites within the M2e domain. The lack of appreciable binding of the human mAbs to M2e-derived linear peptides precluded a synthetic-peptide approach to fine-structure mapping of their epitopes. Instead, binding of the mAbs to M2e alanine substitution mutants and naturally occurring M2 variants that were expressed on the surface of cDNA-transfected mammalian cells was quantified by flow cytometry. Binding experiments with a panel of M2 mutant proteins where each position in the 23-amino acid M2 ectodomain was substituted with alanine revealed that the first (S), fourth (T), and fifth (E) positions of the mature (methionine-clipped) M2 polypeptide were critical for binding of both TCN-031 and TCN-032 (Fig. 3A) . In contrast, the binding of ch14C2 was selectively diminished when alanine was substituted at position 14 of mature M2 (Fig. 3A) . These observations were confirmed in studies with a panel of divergent, naturally occurring M2 variants; substitution with proline at position 4 (Table S4: and A/chicken/Hong Kong/YU427/2003 H9N2) and glycine at position 5 (Table S4: A/chicken/Hong Kong/SF1/2003 H9N2) correlated with diminished binding of the human anti-M2e mAbs but not ch14C2 ( Fig. 3B and Table S4 ). These results suggest that both TCN-031 and TCN-032 recognize a core sequence of SLLTE at positions 1 to 5 of the N terminus of mature M2e. This theory is supported by data which show that these mAbs compete effectively with each other for binding to M2e expressed on the surface of CHO cells (Fig. S3) . In contrast, our results indicate that ch14C2 binds to a site that is spatially distinct and downstream of the SLLTE core that is recognized by the human anti-M2e mAbs. Indeed, previous studies have shown that 14C2 binds a relatively broad, linear epitope with the sequence EVERTPIRNEW at positions 5 to 14 of processed M2e (13) .
Although the epitopes recognized by TCN-031 and TCN-032 are likely very similar, there were some differences between these human mAbs in their binding to several of the M2e mutants. For example, TCN-031 appears to have a greater dependence than TCN-032 on residues 2 (L) and 3 (L) of the mature M2e sequence (Fig. 3A) . The V H regions of these two human mAbs use different variable, diversity, and joining gene segments, which may explain the minor differences in binding observed between these mAbs. Interestingly, despite the differences in their V H make-up, these human mAbs use the same germ-line κ-chain V gene segments, albeit with distinct κ-chain joining segments.
Localization of the binding region of the human anti-M2e mAbs at the N-terminal region of M2e is especially significant in light of the remarkably high-sequence conservation in this part of the polypeptide among influenza A viruses. The viral M gene segment that encodes M2 also encodes the internal viral protein M1 via differential splicing. However, the splice site is located downstream of the shared N terminus of M2 and M1, resulting in two distinct mature polypeptides with an identical 8-amino acid N-terminal sequence (30). Options for viral escape from host anti-M2e antibodies that bind this region might be limited, as escape mutations in the Nterminal region would result in changes to not just M2 but also the M1 protein. Indeed, this N-terminal 8-amino acid segment of M2e shows nearly complete identity in the 1,364 unique full-length M2 variants cataloged in the National Center for Biotechnology Information (NCBI) Influenza Database (http://www.ncbi.nlm.nih. gov/genomes/FLU/Database/multiple.cgi); much lower levels of conservation are seen in M2e sequences downstream of this region (Fig. 3C) . In fact, the core human anti-M2e antibody epitope SLLTE is present in~98% of the 1,364 unique full-length M2e sequences cataloged in the NCBI Influenza Database, including 97, 98, and 98% of the human, swine, and avian viruses, respectively. This finding contrasts to the much lower conservation within the linear binding sites of anti-M2e mAbs elicited by immunization with M2e peptides or proteins. For example, 14C2 and Z3G1 (13) bind sequences that are conserved in less than 40% of influenza A viruses, and conservation within this region is even lower in avian and swine viruses (Table S5) .
The linear M2e epitopes recognized by peptide-elicited antibodies may be more sensitive to escape mutations and natural substitutions that are present in some viral isolates. For example, P10L and P10H escape mutations to mAb 14C2 have been mapped to the central portion of M2e (31) and those same substitutions also occur in M2e variants from some highly pathogenic H5N1 strains. We have found that the human mAbs TCN-031 and TCN-032 but not ch14C2 bind to the M2 variant from the H5N1 virus A/Hong Kong/483/97 (HK), which contains the P10L substitution ( Fig. 3B and Table S4 ). Thus, monoclonal antibodies with specificities similar to that of 14C2 are likely to have limited utility as broad spectrum therapeutic agents.
In the examination of five human subjects, we found 17 unique anti-M2e antibodies that bind the conserved N-terminal region of M2e, but did not observe IgG-reactivity with M2e-derived peptides that contain the linear epitopes recognized by 14C2 and other peptide-elicited antibodies. In contrast to the apparently uniform antibody response to M2e in naturally infected or vaccinated humans, mice immunized with M2e-derived peptides produced antibodies with a range of specificities within M2e, including the conserved N terminus and also downstream regions (15) . It is tempting to speculate that the human immune system has evolved a humoral response that exclusively targets the highly conserved N-terminal segment of M2e rather than the more divergent, and thus less sustainably protective, downstream sites. Despite the lack of evidence for human antibodies that recognize this internal region of M2e, analysis of the evolution of the M gene suggests that this region of M2e is under strong positive selection in human influenza viruses (32). One explanation for this finding is that selective pressure is being directed at this internal region by immune mechanisms other than antibodies. For example, human T-cell epitopes have been mapped to these internal M2e sites (33).
Recognition of 2009 H1N1 S-OIV. Broadly protective anti-influenza mAbs could be used in passive immunotherapy to protect or treat humans in the event of outbreaks from highly pathogenic, pandemic viral strains. A critical test of the potential for such mAbs as immunotherapeutic agents is whether they are capable of recognizing virus strains that may evolve from future viral reassortment events. As a case in point, the human anti-M2e mAbs TCN-031 and TCN-032 were tested for their ability to recognize the current H1N1 swine-origin pandemic strain (S-OIV). These mAbs were derived from human blood samples taken in 2007 or earlier, before the time that this strain is thought to have emerged in humans (34). Both human mAbs bound to MDCK cells infected with A/California/4/2009 (S-OIV H1N1, pandemic) and A/Memphis/14/1996 (H1N1, seasonal), whereas ch14C2 bound only to cells infected with the seasonal virus (Fig. 4) . If this broad binding behavior proves to correlate with protection, as was the case with A/Vietnam/1203/2004 and A/Puerto Rico/8/34, then these human mAbs might be useful to prevent or treat the S-OIV pandemic strain or possibly other pandemic strains that might emerge in the future.
Although it is remarkable that humans have the capability to make antibodies that may confer nearly universal protection against influenza infection, the discovery of this heretofore undescribed class of antibodies raises the question of why this virus is able to mount a productive infection in immunocompe- tent individuals at all. This apparent paradox may be explained by the nature of the protective M2e epitope and its relative immunogenicity. It has been noted by others that M2e appears to exhibit low immunogenicity in humans (35, 36), especially when compared with the immunodominant virus glycoproteins HA and NA. Therefore, protective anti-M2e antibodies may exist in many individuals but at suboptimal titers. In support of this notion is our observation that most individuals did not display a detectable humoral response to M2e. We observed that fewer than 20% (23/140) of the individuals that we sampled in our cohort of healthy subjects had detectable serum levels of antiM2e antibodies. The reasons for this phenomenon are not clear, but a similar situation exists in human CMV, where only a minority of human CMV-seropositive subjects has measurable antibodies to the broadly conserved, neutralizing AD2 epitope within the gB complex of human CMV (25, 37, 38).
An important requirement for an immunotherapeutic solution to the influenza threat will be the identification of protective epitopes that are conserved in preexisting and emerging viruses. Using large-scale sampling of the human immune response to native influenza M2, we have identified a naturally immunogenic and protective epitope within the highly conserved N-terminal region of M2e. Human antibodies directed to this epitope, including those described in the present study, may be useful for the prevention and treatment of pandemic and seasonal influenza.
Materials and Methods
A detailed description of all of the experimental procedures is provided in SI Materials and Methods. Briefly, human peripheral blood mononuclear cells (PBMC), or memory B cells that were enriched from PBMC, were collected and setup in a short-term culture in the presence of feeder cells before the culture supernatants were screened for antibody binding to M2 protein expressed on HEK 293 cells stably transfected with influenza virus M2 (H1N1 A/Fort Worth/ 50). M2e-specific monoclonal antibodies were reconstituted by isolating the mRNA from lysed B-cell cultures followed by reverse transcription of heavy chain, κ-or λ-light chain, variable domain genes with gene-specific primers and PCR amplification using V H , Vκ, and Vλ family-specific primers with flanking restriction sites for cloning into expression vectors.
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Reconstitution of Recombinant mAbs from B-Cell Cultures. Messenger RNA was isolated from lysed B-cell cultures using magnetic beads (Ambion). After reverse transcription with gene-specific primers, variable domain genes were PCR-amplified using V H , Vκ, and Vλ family-specific primers with flanking restriction sites (1). PCR reactions producing an amplicon of the expected size were identified using 96-well E-gels (Invitrogen) and the variable domain amplicons were cloned into the pTT5 expression vector (National Research of Canada, Ottawa, Canada) containing human IgG1-, Igκ-, or Igλ-constant regions. Each V H pool was combined with the corresponding Vκ, or Vλ pools from individual BCC wells and was transiently transfected in 293-6E cells to generate recombinant antibody. Conditioned media was harvested 3 to 5 d after transfection and assayed for antibody binding to M2 protein expressed on HEK 293 cells. Individual clones were isolated from positive pools and unique V H and V L genes were identified by sequencing. From these, monoclonal antibodies were subsequently expressed and reassayed for binding activity.
ELISA. To detect viral antigen, either 10.2 μg/mL UV-inactivated H1N1 A/Puerto Rico/8/34 (PR8) virus (Advanced Biotechnologies, Inc.) was passively adsorbed to 384-well plates in 25 μL PBS/ well for 16 h at 4°C, or PR8 inactivated by β-propiolactone (Advanced Biotechnologies, Inc.) was biotinylated (EZ-Link Sulfo-NHS-LC-Biotin, Pierce) and likewise adsorbed to plates coated with neutravidin (Pierce). Virus-coated and biotinylated virus-coated plates were blocked with PBS containing 1% milk or BSA, respectively. Binding of mAbs at the indicated concentrations was detected with HRP-conjugated goat anti-human Fc antibody (Pierce) and visualized with TMB substrate (ThermoFisher). The M2e peptide, SLLTEVETPIRNEWGCRCNDSSD (Genscript) was passively adsorbed at 1 μg/mL and antibody binding to the peptide was detected by the same method. Fig. 2 A and  B) or six groups of five mice intranasally with 5 × LD 50 A/Puerto Rico/8/34 (Fig. 2 C and D) . At 24, 72, and 120 h postinfection, the mice received i.p. injections of a 400-μg/200-μL dose of the anti-M2e mAbs TCN-031 TCN-032, control human mAb 2N9, control chimeric mAb ch14C2, PBS, or were left untreated. Mice were weighed daily for 2 wk and were killed when weight loss exceeded 20% (H5N1 study shown in Fig. 2 A and B and H1N1 study shown in Fig. 2 C and D) of the preinfection body weight.
Pathological Assessment in Lung, Liver, and Brain of Mice Treated with Anti-M2e mAbs TCN-031 and TCN-032 After Challenge with H5N1 A/Vietnam/1203/04. Lung, liver, and brain issues were collected from three animals per group on day 6 postviral challenge, formalin-fixed, and embedded in paraffin. Paraffin-embedded tissues were cut into 5-μm sections and mounted on glass slides. One replicate slide was stained with H&E and the other replicate slide was processed for immunohistological staining with an anti-VN1203 rabbit antibody using the Dako EnVision System. Histological changes were evaluated under a light microscope. Affinity Measurement of Anti-M2e mAbs. Fabs of mAbs TCN-031, TCN-032, and ch14C2 were used to measure the binding affinity to M2 on purified H1N1 A/Puerto Rico/8/34 influenza A virus (Advanced Biotechnologies Inc.) via Biacore analysis. Virus diluted to 1 × 10 9 viral particles/mL in PBS at 20°C was directly coupled to the sensor chip via amine linkage. Fabs were tested at 1, 3, 9, 27, and 81 nM for binding to virus at 25°C using a Biacore T100. The results are from one experiment.
Antibody-Dependent Cell-Mediated Cytotoxicity. MDCK cells were infected with A/Solomon Island/3/06 (H1N1) influenza virus (Virapur) at a MOI of 3 for 4 h, after which the media was replaced. Cells were harvested the next day and treated with 2 μg/mL of either TCN-031, TCN-032, or 2N9 for 1 h, washed, and resuspended in phenol red-free RPMI supplemented with 5% FBS, penicillin/streptomycin, glutamax, and β-mercaptoethanol (complete RPMI). Human natural killer (NK) cells were purified by depletion of non-NK PBMC using the MACS NK Cell Isolation Kit (Miltenyi Biotec). After washing once with PBS, the NK cells were resuspended in complete RPMI. The infected MDCK cells were plated at 10 4 cells per well and 50 μL per well in 96-well Vbottom plates. NK cells were added in 50 μL/well at the indicated effector:target ratios. Alternatively, as controls, complete RPMI or 10% TritonX-100 lysis buffer was added to a total of 100 μL/ well. The plates were incubated at 37°C for 4 h. Samples were analyzed in triplicate. Supernatants (50 μL per well) were harvested and delivered to a blackwall 96-well flatbottom plate. Cytolysis was quantified by the detection of released lactate dehydrogenase using the CytoTox 96 Nonradioactive Cytotoxicity Assay kit (Promega). Cytolysis values were derived by the formula of % Specific Release = 100 × (experimental release − spontaneous release)/(detergent release − spontaneous release).
Complement-Dependent Cytolysis. The stable CHO transfectant cell lines expressing full length HK-M2 or a mock control were treated with 5 μg/mL of mAbs TCN-031, TCN-032, ch14C2, or negative control 5J12, followed by washing with PBS containing 1% FBS. The cells were then incubated with 25% human complement (Sigma) in PBS containing 1% FBS at 37°C for 1 h. Cells were again washed, and subsequently stained with propidium iodide followed by analysis by FACS. Pathological changes and viral antigens were detected in the lungs of all virus-challenged mice. The mice had similar lung lesions across all groups, although mice in the TCN-031 and TCN-032 groups had a tendency toward less viral antigen expression in the lung. In the brain and liver, lesions were not detected in mice in the TCN-31 group and only one of three mice in the TCN-032 group showed some evidence of viral antigens in the brain. Pathological changes/viral antigens: +++, severe/many; ++, moderate/moderate; +, mild/few; ± scant/rare; −, not observed/negative. Unique M2e sequences used to calculate percent conservation were obtained from The Influenza Virus Resource at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). The reported epitope for each mAb is shown in brackets.
